



DISA Limited

(Company Registration No. 197501110N)

(Incorporated in the Republic of Singapore)

NEWS RELEASE:


DLL Completes Trial Deployment of Automated Visual Acuity Test Device in a Major Public Hospital in Singapore, Accelerating Commercialisation Efforts with Strategic New Hires

- **Globally, the Group's Automated Visual Acuity Test ("AVAT") is one of the first devices that can automate ophthalmology screening, which is essential for eye-care related diseases**
- **Recently completed the first trial deployment of its AVAT device in a major public hospital in Singapore**
- **Ongoing trials with other public and private eye clinics across Singapore to further expand market presence**
- **New engineering and regulatory specialists added to the team to accelerate commercialisation efforts**
- **Video demo of AVAT at <https://www.youtube.com/watch?v=GrQSHMd35PM>**

SINGAPORE – 8 April, 2024 — DISA Limited ("**DISA**" or the "**Company**", and together with its subsidiaries, the "**Group**") is pleased to share the recent milestones of Digital Life Line Pte. Ltd. ("**DLL**"), a subsidiary of DiSa Digital Safety Pte. Ltd., a wholly owned subsidiary of the Company.

Incorporated in 2021, DLL is a Singapore-based ISO13485-certified medical technology company that provides digital, AI-powered diagnostic ophthalmology solutions to enable community-based vision screening for early detection and treatment of vision impairment.

AVAT is the result of years of dedicated research and development work by the Department of Ophthalmology at the National University Hospital ("**NUH**") and Centre for Innovation and Precision Eye Health at the Yong Loo Lin School of Medicine, National University of Singapore ("**NUS Medicine**") to alleviate operational challenges with visual acuity ("**VA**") testing.



Commercial Deployment of AVAT Expected in 2nd Quarter of 2024

DLL has recently completed the first trial deployment of its AVAT device in a major public hospital in Singapore, with ongoing trials with other public and private eye clinics across Singapore to further expand its market presence.

Based on a “Hardware-as-a-Service” business model, AVAT’s first commercial deployment is expected in the second quarter of 2024, which also marks a significant step forward towards DLL’s mission to improve accessibility and convenience for accurate vision screening via automation and technology innovation.

Globally, AVAT is one of the first devices that can automate ophthalmology screening. With its adaptive test algorithm, proprietary afocal optics, and user-friendly interface within a tabletop footprint, AVAT offers precise and efficient vision testing, contributing to enhanced patient care and diagnostic accuracy.

Mr. Eddie Chng, the Managing Director and Chief Executive Officer of the Group said, “Within 8 months, we have made significant progress in the field of ophthalmology screening and diagnostics. Our team’s dedication and ingenuity have been instrumental in achieving these milestones, and I am incredibly proud of their hard work and commitment to excellence.

With the successful deployment of our AVAT device in Singapore, it is another testament to our commitment to deliver tangible value to our clinical partners and patients with our technology innovations.

To meet the increasing demand for eye-related healthcare needs, we aim to empower eyecare professionals with the DLL’s growing portfolio of advanced diagnostic tools, improving patient outcomes and lowering healthcare costs by facilitating timely interventions and personalised care.”



“Building on the work by clinician innovators and nurse practitioners, we are already witnessing positive feedback from healthcare professionals and patients alike, underscoring the value and effectiveness of our innovative solution,” said Dr. Poh Weijie, the Chief Scientist of DLL. “We are also pleased to report growing interest from overseas eye clinics, indicating the potential for widespread adoption of AVAT in the Asia-Pacific. The recognition and enthusiasm demonstrated by international healthcare institutions validate the efficacy and reliability of our technology on a global scale, positioning us as a vital asset in ophthalmic diagnostics.”

Welcomes New Engineering and Regulatory Specialists to DLL

As part of DLL’s market expansion strategy, the Group is delighted to welcome two new valuable additions to DLL’s team, where their expertise and insight will be instrumental in further enhancing the functionality and usability of DLL’s medical device solutions, ensuring alignment with the evolving needs of healthcare professionals and patients.

Firstly, the Group welcomes Mr. Muhammad Azri Bin Razali, who has joined DLL as Chief Engineer. Having worked with clinicians to develop solutions that address gaps in diagnosis and treatment, Mr. Muhammad Azri has more than a decade of experience in hardware and software development with deep knowledge in multiple domains, including image processing, rapid prototyping and translational research in ophthalmology.

Secondly, the Group has enlisted the expertise of Dr. Geetha Ganesh, a seasoned regulatory affairs specialist, to navigate the complex landscape of medical device regulations and compliance. Dr. Ganesh has been extensively involved for the last 20 years in the fields of global regulatory affairs of medical devices, drugs, and pharmaceutical products, including having completed regulatory audits that cover ISO 13485, PIC GMP, WHO-GMP, CFR (Code of Federal Regulation), TGA (TGA –Australia Medical Device Approval), MDR/ IVDR (CE certification), Singapore (SS620), Good Distribution Practice of Medical Devices in Malaysia (GDPMD), GLP, MDSAP, ISO 15189 and GDP. Her profound understanding of regulatory requirements will be vital in accelerating DLL's commercialisation efforts and facilitating regulatory approval processes for its products and services.

Mr. Eddie Chng added, “Coupled with the burgeoning interest from overseas eye clinics and the strategic additions to our team, we are optimistic that we are well positioned to leverage these milestones as catalysts for new growth opportunities ahead.”

-----End-----

Issued on behalf of DISA Limited by 8PR Asia Pte. Ltd.

Media & Investor Contacts:



Mr. Alex TAN
Mobile: +65 9451 5252
Email: alex.tan@8prasia.com

About DISA Limited (SGX Code - 532.SI / Bloomberg - DISA:SP / Reuters - DISA.SI)

DISA Limited, is a publicly traded company on the Singapore Catalist Stock Exchange. Together with our subsidiaries, the Group focuses on pioneering and adopting the latest technology innovations to enhance outcomes, reduce costs, improve efficiencies within the healthcare and consumer industry.

Bringing scaled solutions that thrive in a changing world, DiSa leverages on our strong in-house R&D capabilities to continuously pursue new innovations and disruptive technology (such as Artificial Intelligence, Internet of Things, etc.) for the digitalisation of product and services that optimises efficiency and quality standards in our targeted markets.

More information is available at www.disa.sg.

This announcement has been reviewed by the Company's sponsor, SAC Capital Private Limited (“Sponsor”). This announcement has not been examined or approved by the Singapore Exchange Securities Trading Limited (“SGX-ST”) and the SGX-ST assumes no responsibility for the contents of this announcement including the correctness of any of the statements or opinions made or reports contained in this announcement.

*The contact person for the Sponsor is Ms. Lee Khai Yinn, Registered Professional, SAC Capital Private Limited.
Address: 1 Robinson Road, #21-00 AIA Tower, Singapore 048542
Telephone number: +65 6232 3210*